Multi-omic and functional screening reveal targetable vulnerabilities in *TP53* **mutated** multiple myeloma

Short title: Novel vulnerabilities in *TP53* mutated myeloma

Dimitrios Tsallos¹, Nemo Ikonen¹, Juho J. Miettinen¹, Muntasir Mamun Majumder¹, Samuli Eldfors^{1,2}, Imre Västrik¹, Alun Parsons¹, Minna Suvela¹, Katie Dunphy³, Paul Dowling³, Despina Bazou⁴, Peter O'Gorman⁵, Juha Lievonen⁶, Raija Silvennoinen⁶, Pekka Anttila⁶, Caroline A. $Heckman¹$

1. Ins'tute for Molecular Medicine Finland, Helsinki Ins'tute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;

2. Massachusetts General Hospital Cancer Center, Charlestown, MA, and Department of Medicine, Harvard Medical School, Boston, MA, USA;

3*. Department of Biology, Maynooth University, W23 F2K8, Maynooth, Ireland;*

4. School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland;

5*. Department of Haematology, Mater Misericordiae University Hospital, D07 WKW8, Dublin, Ireland;*

6*. Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University*

of Helsinki, Helsinki, Finland

Corresponding author:

Caroline A. Heckman, PhD Institute for Molecular Medicine Finland - FIMM University of Helsinki Tukholmankatu 8 (P.O. Box 20) FI-00290 Helsinki Finland c: +358 50 4156769 caroline.heckman@helsinki.fi

Abstract: 234 words

Text: 4324 words

Figures: 7 (5 figures and 2 tables)

References: 40 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

KEY POINTS

TP53 mutation in myeloma confers sensitivity to multiple compounds, including approved 3 drugs, irrespective of del(17p) status.

5 TP53 mutated myeloma links to higher expression of drug targets involved in cell proliferation, 6 mRNA processing, and chromatin modulation.

ABSTRACT

9 Despite development of several effective therapies for multiple myeloma (MM), the prognosis 10 of patients with partial deletion of chromosome 17 (del(17p)) and *TP53* aberrations remains poor. By applying comprehensive multi-omics profiling analyses (whole exome and transcriptome sequencing plus proteomics) and functional *ex vivo* drug screening to samples from 167 patients with MM, we uncovered novel therapeutic vulnerabilities specific to *TP53* mutated MM. Our findings revealed a distinct sensitivity profile to a range of inhibitors (mitotic, topoisomerase, HDAC, HSP90, IGF1R and PI3K/AKT/mTOR inhibitors) irrespective of 17p deletion status. Conversely, no increase in sensitivity was observed for monoallelic *TP53* (del(17p) with WT *TP53*) when compared to other samples, highlighting the remaining unmet clinical need. Notably, plicamycin, an RNA synthesis inhibitor linked to modulation of chromatin structure and increased 20 transcription, emerged as particularly efficacious for *TP53* mutated MM. The increased sensitivity correlated with higher protein expression of the drug targets: HDAC2, HSP90AA1 and multiple ribosomal subunits. Additionally, we observed increased RNA expression of G2M checkpoint, E2F targets and mTORC1 signaling in our cohort and the MMRF-CoMMpass (NCT01454297) study in *TP53* mutated MM. Harmonization of multi- omics data with *ex vivo* drug screening results revealed that *TP53* mutated MM is 26 functionally distinct from MM with monoallelic *TP53*, and demonstrates that MM with mutated *TP53*, with and without del(17p), may be targetable by approved drugs. These results 28 further indicate the need for regular monitoring by sequencing to identify these patients.

29 **INTRODUCTION**

30 Multiple myeloma (MM) is a complex and incurable disease characterized by a clonal 31 proliferation of plasma cells in the bone marrow (BM). Significant advancements in MM 32 treatment modalities have been made over the past decades¹, but despite the availability of 33 novel treatments, the clinical and genetic heterogeneity of the disease continues to 34 complicate prognosis and therapeutic strategies¹. Genetic aberrations traditionally detected 35 by fluorescence *in situ* hybridization (FISH) are known to play a pivotal role in MM progression 36 and treatment outcomes². Transitioning from FISH to next generation sequencing (NGS) could 37 enhance the detection of recurrent aberrations to driver genes such as *TP53*, offering a more 38 comprehensive genomic landscape and potentially refining therapeutic approaches and 39 management of patients with MM².

40 Among the genetic aberrations influencing MM prognosis, deletion of the p arm of 41 chromosome 17, del(17p), stands out as a high-risk factor with profound implications for 42 patient prognosis and response to treatment^{2,3}. Del(17p) is identified in 10% of patients with 43 newly diagnosed MM and is primarily monoallelic. Importantly, the *TP53* gene is located 44 within the minimally deleted region on 17p13. The co-occurrence of del(17p) together with 45 *TP53* mutation, often referred to as 'double hit' MM, is associated with worse prognosis^{2,3}. 46 TP53 mutations alone are detected in 1-7% of newly diagnosed patients with MM^{4–6}. However, 47 both *TP53* mutation and del(17p) aberrations are more prevalent after relapse occurring in 48 approximately 23-45% of cases^{5,7}. The emergence of *TP53* mutations as a key risk factor for 49 stratification is evident given the significant adverse prognosis, even in the absence of 50 del(17p)^{6,8}. Moreover, *TP53* mutations in various cancers can lead to gain-of-function or 51 dominant negative phenotypes, altering treatment response⁹.

52 Functional *ex vivo* drug sensitivity testing of patients' tumor cells to hundreds of inhibitors can 53 reveal cell dependencies and molecular vulnerabilities while accounting for patient 54 variability^{10–13}. Here we show that integration of drug sensitivity data with genomic, 55 transcriptomic, and proteomic data from the same samples revealed a deeper functional view 56 of the impact of *TP53* aberrations in CD138+ MM cells. The presence of *TP53* mutation 57 associated with increased sensitivity to approved drugs, including conventional 58 chemotherapeutics, irrespective of del(17p) status. In contrast, monoallelic *TP53* samples had 59 a distinct molecular profile without a significant change in *ex vivo* drug responses. Overall, we 60 explored novel therapeutic options for *TP53* aberrations in MM and identified vulnerabilities

3

- 61 associated with *TP53* mutation to multiple compounds, providing a foundation for targeted 62 treatment strategies to improve patient outcome.
- 63

64 **MATERIALS AND METHODS**

65 *Patients and samples*

 Bone marrow (BM) aspirates and skin biopsies were collected from patients under approved protocols (239/13/03/00/2010 and 303/13/03/01/2011) in line with the Declaration of 68 Helsinki as previously described¹⁰. Following Ficoll (GE Healthcare) gradient separation of the mononuclear cell fraction, CD138+ cells were enriched by immunomagnetic bead separation (StemCell Technologies) and used for downstream assays. Interphase FISH was conducted 71 according to the European Myeloma Network 2012 guidelines²⁹. Patient characteristics and assays performed are detailed in **Table 1**.

73 *Ex vivo drug screening and analysis*

74 Drug sensitivity testing was conducted using an established *ex vivo* drug screening method on 75 CD138+ cells, with viability measured by CellTiter-Glo reagent (Promega) after 72 hours $10-12$. 76 BM CD138+ cells were added to pre-drugged plates, which contained up to 348 compounds 77 (**supplemental Table 1**). Quality control analysis, dose response curve fitting, and drug 78 sensitivity scores (DSS) were calculated as previously described¹⁵.

79 *Whole Exome Sequencing*

80 Genomic DNA was extracted from skin biopsies and CD138+ BM cells using the Qiagen DNeasy 81 Blood & Tissue kit or the Qiagen AllPrep DNA/RNA/miRNA Universal kit. The isolated DNA was 82 processed, exome libraries prepared and sequenced as described previously $11,31$. Somatic 83 mutations were identified and annotated using established methods³². The presence of a 84 mutation is considered if the variant frequency exceeded 5% (somatic p-value \leq 0.05).

85 *RNA Sequencing*

 RNA from CD138+ cells isolated using the Qiagen AllPrep DNA/RNA/miRNA Universal kit, RNAseq libraries were prepared using ribosome depletion, data pre-processing and the 88 analysis pipeline were carried out as described earlier³³. Differential gene expression (DGE) 89 analysis was performed using DESeq2 R package $(1.36.0)^{34}$ from log₂CPM raw counts calculated with edgeR after TMM normalized. Within DESeq2, raw count data were filtered to remove genes with less than 10 reads in at least 95% of the samples. For the gene set

92 enrichment analysis, we used clusterProfiler $(4.4.4)^{35}$ package and MSigDB (7.5.1) and from that H (Hallmark) and C5 (GO) genesets, excluding human phenotype ontology sets (HPO) 94 ^{36,37}.

Label-Free LC-MS/MS Analysis and Data Processing of CD138+ cells

 500 ng of each digested sample was analysed using Q-Exactive (ThermoFisher Scientific, Hemel Hempstead, UK) high-resolution accurate mass spectrometer connected to a Dionex Ultimate 3000 (RSLCnano) chromatography system (ThermoFisher Scientific, Hemel Hempstead, UK). Peptides were separated and data acquired with MS/MS scans. Protein identification and label-free quantification (LFQ) normalization were performed using MaxQuant v1.5.2.8 [\(http://www.maxquant.org\)](http://www.maxquant.org/), with subsequent data analysis using Perseus. In our figures, uniprot accession IDs are presented as gene symbol IDs. More details are provided in the **supplemental Methods**.

Validation using public data

 We utilized the IA21 version of the MMRF-CoMMpass study (NCT01454297), available from MMRF research gateway (https://research.themmrf.org/). Only CD138+ BM samples at 107 diagnosis were selected. The del(17p) status was determined using available seqFISH data³⁸. DGE analysis was performed as described above. Survival analysis was performed in R using 109 survival $(3.5-7)^{39}$ and survminer $(0.4.9)^{40}$ packages.

Statistical Analyses

 Statistical analysis was done in R. Normality of the data was assessed using Shapiro-Wilk test and based on the result either the Welch Two Sample t-test or Wilcoxon rank-sum test were applied to subsequent analysis. Categorical data was analyzed using Fisher's exact test or chi-114 square test according to the sample size. Kruskal-Wallis Test was applied to estimate the difference between the age distribution of the groups. Resulted p-values were adjusted with Benjamini-Hochberg. Survival analysis employed the Kaplan-Meier method and Cox 117 proportional hazards models.

RESULTS

Study sample characteristics

 Our study utilized data from 167 individuals receiving treatment throughout Finland. Collected BM samples were processed for mononuclear cell selection and immunomagnetic

 separation of CD138+ cells. DNA from the selected cells and a matching skin biopsy underwent whole exome sequencing to identify somatic mutations. Subsets of CD138+ cells were also used for bulk RNA sequencing and proteomic evaluation (**Figure 1A, B**). Additionally, the *ex vivo* sensitivity of the same CD138+ MM patient cells was assessed against an oncology drug collection of 348 small molecule inhibitors, with 153 total screened samples (**supplemental Table S1**). Other clinical data, such as karyotyping, was available and summarized information is provided in **Table 1**.

- 130 When focusing on *TP53* aberrations, the use of next-generation sequencing provides a more 131 detailed view of the patient subpopulations as presented in the MMRF-CoMMpass cohort 132 (**Figure 1C**). Characteristically, *TP53* mutation becomes more prevalent at relapse (15.2%) 133 compared to diagnosis (7.2%). Given that mutated *TP53* leads to functional impairment of 134 wild-type (WT) p53 protein^{9,14}, we grouped all samples with *TP53* mutation (*TP53*^{mut/-} and 135 *TP53^{mut/WT}*) in one category. This includes samples with additional detection of del(17p), also 136 known as double-hit MM. Samples containing only wild-type copies of *TP53* but presented 137 del(17p) from karyotyping are referred to as monoallelic *TP53* from here on. Five samples 138 lacking sequencing results but with a detected del(17p) karyotype are also included in this 139 category, for a total of 19 monoallelic *TP53* patient samples. The remaining samples (n = 130) 140 were *TP53* WT*.*
- 141

142 Presence of TP53 mutation is associated with increased sensitivity to multiple drugs

143 In search of novel therapeutic vulnerabilities in high-risk patients harboring *TP53* aberrations, 144 we analyzed data from our *ex vivo* drug screening platform. To measure the drug sensitivity of 145 the samples, we used the drug sensitivity score (DSS), which is a modified version of the area 146 under the curve. The DSS allows for comparison of dose-response curves across a range of 147 concentrations, providing a single measure of the sensitivity of the cancer cells to the drug¹⁵. 148 Confirming the difficulty to treat del(17p) patients, CD138+ MM cells with monoallelic *TP53* 149 showed no significant increase in *ex vivo* sensitivity to the tested compounds. Conversely, 150 samples with *TP53* mutation, regardless of the presence of del(17p), displayed higher 151 sensitivity to certain mitotic inhibitors and inhibitors targeting RNA synthesis, HDAC, 152 topoisomerase, HSP90, and the PI3K/AKT/mTOR pathway (**Figure 2A,B; supplemental Table** 153 **S2**). The mutant p53 targeting compound APR-246 demonstrated enhanced activity in *TP53*

154 mutated MM, suggesting that it effectively reactivates the mutant p53 protein leading to cell death. The biological significance of the specific grouping is also observed for monoallelic *TP53* MM where increased resistance to the MDM2 antagonists idasanutlin (median difference = - 6.8; p-value = 0.074) and nutlin-3 (median difference = -2.6; p-value = 0.014) was observed. Resistance to MDM2 antagonists suggests the reduced availability of p53 in samples with 159 monoallelic *TP53*, while the activity of APR-246 highlights the dominant effect of the mutant 160 p53 protein (**Figure 2C**). The impact of *TP53* mutation on *ex vivo* drug response is highlighted by the comparison of DSS between *TP53* mutated and monoallelic *TP53* samples (**supplemental Figure S1**).

163 The most remarkable increase in sensitivity of *TP53* mutated MM samples was observed for 164 plicamycin, an RNA synthesis inhibitor. The response to plicamycin was greater than that to 165 another RNA and DNA synthesis inhibitor, dactinomycin, which also showed a significant 166 increase in activity. Multiple conventional chemotherapeutics showed increased activity in 167 samples with *TP53* mutation, specifically mitotic inhibitors (vinorelbine, paclitaxel, docetaxel, 168 vincristine, ABT-751, patupilone) and topoisomerase inhibitors (teniposide, irinotecan, 169 daunarubicin, camptothecin, topotecan, etoposide, doxorubicin, idarubicin). Many 170 chemotherapeutics were tested on fewer samples, however, the consistency of the increased 171 sensitivity on similar compounds supports the observation that *TP53* mutated cells are more 172 sensitive to these drug classes (supplemental Table S2).

173 This increased activity was also evident with HDAC inhibitors quisinostat and panobinostat, 174 both approved treatments. In a smaller set of samples, CUDC-101, targeting class I/II HDAC 175 and EGFR also showed significantly increased activity in *TP53* mutated MM samples, while 176 belinostat showed increased, but not a significant difference in activity (median difference = 177 9.5; p-value = 0.072).

178 The heightened activity of PI3K/AKT/mTOR pathway inhibitors in *TP53* mutated MM CD138+ 179 cells suggested a potential dependency on growth signals involving this pathway. We showed 180 increased *ex vivo* sensitivity to vistusertib, omipalisib, pictilisib, temsirolimus, and dactolisib. 181 Additionally, kinase inhibitors tirbanibulin, GSK-1904529A, BMS-754807, and ruxolitinib all 182 demonstrated increased activity in *TP53* mutated MM samples. GSK-1904529A and BMS-183 754807 target IGF1-R and ruxolitinib specifically targets JAK1 and JAK2 kinases, which are 184 upstream of PI3K, AKT and mTOR. The HSP90 inhibitor tanespimycin, which indirectly 185 suppresses the PI3K/AKT/mTOR pathway¹⁶, also showed significant increase in activity towards *TP53* mutated CD138+ cells.

187 To assess the impact of *TP53* mutation frequency on the response to these compounds, we 188 correlated the response of each sample with the mutation frequency (supplemental Figure 189 S2; supplemental Table S3). To establish correlation, we selected compounds tested in at least 5 samples and highlighted compounds with significant difference observed in *TP53* mutated MM (**supplemental Figure S2A)**. Except for JQ1, most compounds showed weak and non-192 significant correlation to mutation frequency, probably owing to overall limited selective toxicity of the compounds.

TP53 mutations frequently co-occur with KRAS mutations in MM

 To understand the broader genetic landscape of *TP53* aberrations in MM and search for possible confounding factors in drug response, we explored the frequency of co-occurrence of common mutations. In our cohort, almost half of the samples with *TP53* mutation also had a mutation to *KRAS*, while *KRAS* mutations were rare in samples with monoallelic *TP53* (Fisher's exact test: p = 0.029; OR = 6.44, 95% CI = [1.01, 73.93]; **Figure 3A**). However, *KRAS* mutations were not more likely to be present in *TP53* mutated MM compared to MM with WT *TP53* (Fisher's exact test: p = 0.080; OR = 0.378, 95% CI = [0.12, 1.21]). To assess whether *TP53* and *KRAS* mutation co-occurrence is common in MM, we analyzed diagnostic samples from the MMRF-CoMMpass study (**Figure 3B**). In this cohort, *KRAS* mutations were present in 14 out of 85 samples with *TP53* mutation (16.5% frequency), which was more common than with WT *TP53* (χ² = 5.089, df = 2, p-value = 0.024). To assess the impact of co-occurring *KRAS* mutations on *ex vivo* drug response, we compared the drug sensitivity profiles of *TP53* mutated MM with and without *KRAS* mutation. We found that samples with co-occurring *TP53* and *KRAS* mutations were significantly more resistant to 5 compounds compared to samples with mutated *TP53* and WT *KRAS* (**supplemental Figure S3**, **supplemental Table S4**). *TP53* is often characterized by hotspot mutations, with the location of the mutation having 212 different functional impact on the resulting protein. Using the MMRF-CoMMpass dataset, we found that most mutations in *TP53* were spread across the protein but occurred more frequently in the DNA binding domain (**Figure 2C**). Similarly, in the FIMM cohort, most mutations occurred in the DNA binding domain, with some samples containing more than one

216 mutation (**Table 2**). No other hotspot mutation was detected, in concordance with previous 217 observations in $MM¹⁷$.

218

219 *Differential gene expression analysis reveals a transcriptional profile of enhanced cellular* 220 *proliferation in TP53 mutated MM*

221 To understand the cellular implications and functional impact of *TP53* mutations in MM, we 222 compared RNA sequencing data of *TP53* mutated to WT *TP53* MM samples and applied 223 differential gene expression (DGE) followed by gene set enrichment analysis (GSEA). To 224 explore the consistency of our analysis with a wider cohort, we followed the same steps using 225 data both from the FIMM cohort as well as the MMRF-CoMMpass study.

226 In the FIMM cohort, we compared 15 samples with *TP53* mutation against 77 WT *TP53* 227 samples, from which we identified 1043 differentially expressed genes (p-value \leq 0.05), of 228 which 675 were upregulated and 368 downregulated (**Figure 4A**; **supplemental Tables S5-S7**). 229 From the CoMMpass study samples with RNA sequencing data available, we compared 52 230 samples exhibiting *TP53* mutation (8.6%) against 552 samples with WT *TP53*. This DGE analysis 231 provided 700 differentially expressed genes (adjusted p-value \leq 0.01), of which 458 were 232 upregulated and 232 downregulated (**Figure 4B, supplemental Tables S8-S10**). The results 233 from both datasets were consistent and demonstrated that *TP53* mutated MM is associated 234 with cell proliferation gene expression signatures. The G2M checkpoint, E2F targets and 235 mitotic spindle formation were upregulated in both cohorts (**Figure 4C, D**). In addition to the 236 common findings, the CoMMpass dataset showed a significant upregulation of mTORC1 237 signaling and genes involved in glycolysis. On the other hand, the downregulation of gene sets 238 modulated by NF-kB in response to TNFalpha, hypoxia, response to interferon gamma, and 239 apoptosis were only significant in the FIMM cohort analysis.

240 Additionally, we explored the transcriptional impact of monoallelic *TP53* on both FIMM and 241 CoMMpass cohorts. DGE analysis of the FIMM cohort identified 724 differentially expressed 242 genes (p-value £ 0.05), of which 472 were upregulated and 252 downregulated (**supplemental** 243 **Figure S4A**). From the CoMMpass study samples, we identified 430 differentially expressed 244 genes (adjusted p-value \leq 0.05), of which 230 were upregulated and 200 downregulated 245 (**supplemental Figure S4B**). GSEA revealed an increase in the G2M and E2F gene sets for

246 samples with monoallelic *TP53* only in the larger CoMMpass cohort (**supplemental Figure** 247 **S4C; supplemental Tables S11-S13**).

248

249 *Proteomic profiling reveals elevated drug target expression in TP53 mutated MM*

250 To expand on our understanding of the functional molecular landscape associated with *TP53* 251 mutations in MM, we explored proteomic data produced by LC-MS/MS analysis of CD138+ 252 cells from a subset of our samples. We performed proteomic analysis on 34 samples, of which 253 5 contained *TP53* mutation, 6 had monoallelic *TP53* and 23 were WT *TP53*. Out of the 2753 254 identified proteins, 430 exhibited significant difference between samples with *TP53* mutation 255 compared to WT $TP53$ (Welch Two Sample t-test two sided; p-value \leq 0.05; Figure 5A; 256 **supplemental Table S14**).

 In alignment with the results from GSEA of RNA sequence data, we observed an enrichment 258 of E2F targets and G2M checkpoint proteins. Additionally, MYC targets were upregulated as shown in **Figure 5B**. Analysis using the Gene Ontology (GO) C5 library revealed significant 260 enrichment of proteins associated with transcription processes, such as RNA binding, RNA/mRNA processing, nuclear speckles, and RNA splicing (**Figure 5C**). Notably, the 262 ribonucleoprotein complex gene set, involved in ribosomal functions, including HURNPA3, HNRNPA2B1, SNRPA1, and RNPS1, along with the FACT complex proteins SSRP1 and SUPT16H, were highly expressed in the *TP53* mutated samples (**Figure 5A**; **supplemental Table S14**).Among the gene sets enriched with the selected proteins, we observed downregulation 266 in the immune response and immune markers CD9, CD36 and CD76 suggesting a mechanism of immune evasion. Other significantly downregulated gene sets included those associated 268 with mechanisms of adhesion and secretion. For the full list of gene sets enriched in this analysis see **supplemental Tables S15-S16**.

270 Among the significantly expressed proteins identified, some are notable drug targets. We 271 observed increased expression of HDAC2, which is a target of HDAC inhibitors. This supports 272 the observed sensitivity to specific HDAC inhibitors, including the approved non-selective 273 inhibitors panobinostat and quisinostat, and the dual-acting inhibitor CUDC-101, which 274 targets both HDAC and EGFR pathways. Similarly, we observed significant upregulation of 275 HSP90AA1, the target of HSP90 inhibitor tanespimycin (**supplemental Figure S5;** 276 **supplemental Table S2**). While these single proteins can explain the efficacy of some targeted

277 compounds, the scope is limited by the specificity of the inhibitors and the detectable proteins in our analysis.

 In contrast, comparison of monoallelic *TP53* to WT *TP53* proteomic profiles exhibited 96 significantly expressed proteins, with 45 upregulated and 51 downregulated in the monoallelic *TP53* samples. We observed an increase in gene sets related to protein transport and a decrease in mitochondrial matrix and ribonucleoprotein complex (**supplemental Figure S6; supplemental Tables S17-S18**).

Clinical Implications of TP53 aberrations

 To translate our findings to the clinic and evaluate the impact on prognosis of *TP53* mutations, we leveraged the comprehensive dataset provided by the MMRF-CoMMpass study and investigated the clinical prognosis of patients with or without *TP53* mutation.

 A significant reduction in overall survival (OS) was notable among patients with *TP53* mutation as compared to those with WT *TP53* (OS: HR = 2.004 [95% CI: 1.314-3.057] p = 0.001; **Figure 5D**). Surprisingly, patients with monoallelic loss of *TP53* showed no significant reduction in OS compared to patients with WT *TP53*, but they clearly had shorter progression free survival (OS: HR = 1.264 [95% CI: 0.681-2.343] p = 0.458; PFS: HR = 1.356 [95% CI: 0.997- 1.846] p = 0.053; **Figure 5E**). Patients with monoallelic *TP53* had a median PFS of 530 days (17.4 months) compared to 628 (20.6 months) for patients with *TP53* mutation. This suggests that the presence of *TP53* mutation can lead to a more aggressive disease after the first relapse, possibly because of clonal expansion. Although there is an increase in patients with *TP53* mutation at relapse (**Figure 1**), due to lack of variant allele frequency data in the MMRF-CoMMpass dataset we were not able to explore the clonal evolution of *TP53* mutations.

DISCUSSION

 In our study we provide a comprehensive view and contribute significant insight into the 303 consequences of *TP53* aberrations in MM by applying a multi-omic approach to a large set of 304 patient samples. Functional assessment by *ex vivo* drug sensitivity testing along with genomic, 305 transcriptomic, and proteomic analyses highlight the biological impact of *TP53* mutations and 306 revealed potential treatment vulnerabilities. Notably, our findings discerned distinct 307 differences in *ex vivo* drug responses between MM with *TP53* mutation and MM with

308 monoallelic *TP53* when compared to samples with WT diploid *TP53*. These results were 309 further supported by differences in the genomic, transcriptomic, and proteomic landscapes of 310 these patients. Our research provides novel insights into the vulnerabilities of MM with *TP53* 311 mutations, with or without del(17p), as well as underscoring the need and suggesting 312 potential personalized therapeutic strategies for this high-risk subset of patients for future 313 investigations.

314 The clinical landscape of MM has long been influenced by the presence of del(17p), a well-315 documented adverse prognostic factor². With the advent of sequencing technologies, *TP53* 316 mutations have emerged as a novel prognosis marker in MM $6,17$, yet their distinct functional 317 impact compared to del(17p) has not been fully recognized until now. Our study showed that 318 unlike monoallelic *TP53*, *TP53* mutations in CD138+ cells confer increased sensitivity to 319 multiple small molecule inhibitors. This finding presents opportunities to develop effective 320 treatment strategies that includes conventional chemotherapies and other approved drugs. 321 By focusing on patients with *TP53* mutation, we have the potential to mitigate the risk for 322 almost half of the del(17p) cases, including those with double-hit MM and those with *TP53* 323 mutation and intact chromosome 17. However, our results reaffirm the continued challenges 324 of treating del(17p) MM.

325 Drug sensitivity testing of MM samples from a large cohort of patients demonstrated that MM 326 with *TP53* mutation is vulnerable to multiple approved and investigational drugs with known 327 target profiles. Even at low variant allele frequency (VAF) CD138+ MM cells with a minimum 328 *TP53* mutation VAF of 5% displayed increased sensitivity to a spectrum of compounds, 329 including conventional chemotherapeutics, topoisomerase, RNA synthesis, HDAC, HSP90, 330 IGF1R and PI3K/AKT/mTOR pathway inhibitors. HSP90 and HDAC inhibitors have already been described to have critical roles in the degradation of mutant *TP53* in other types of cancer¹⁸. 332 The increased expression of proteins HSP90AA1 and HDAC2, together with the increased 333 sensitivity to HSP90 and HDAC inhibitors, suggest a critical role for these factors in *TP53* 334 mutated MM cell survival. *TP53* mutations have been previously reported to upregulate *IGF1R* 335 expression and IGF-1 mediated mitogenesis, possibly through reduced p53 levels and 336 increased demand for new ribosomes, leading to MDM2-p53 interaction^{19,20}. Subsequent 337 mTOR pathway activation leads to increased cell proliferation, increased mRNA translation 338 and increased glycolytic activity^{19–21}. The observed increase in expression of ribosomal

339 subunits, together with the enrichment of genes involved in glycolysis and mTORC1 signaling 340 may explain the enhanced vulnerability to IGF1R, PI3K/AKT/mTOR inhibitors.

341 Both gene expression and proteomic analyses showed enrichment of pathways associated 342 with increased cell proliferation in *TP53* mutated MM. Consequently, common 343 chemotherapies including mitotic inhibitors (i.e. paclitaxel and vincristine), intercalating 344 agents (i.e. doxorubicin and gemcitabine) and topoisomerase inhibitors (i.e. topotecan, 345 etoposide and idarubicin) showed increased activity in CD138+ cells with *TP53* mutation. In 346 contrast, CD138+ cells with monoallelic *TP53* did not display an increase in sensitivity to 347 chemotherapies when compared to cells from patients with WT *TP53*.

348 The enhanced sensitivity of *TP53* mutated samples to doxorubicin, plicamycin and 349 dactinomycin may be explained by their mechanisms of action and association with ribosomal 350 biogenesis and mRNA processing $22,23$. Proteomic analysis revealed that proteins belonging to 351 the ribonucleoprotein complex are upregulated in mutated *TP53* and downregulated in 352 monoallelic *TP53* MM. Doxorubicin has been previously shown to inhibit the synthesis of 47S 353 rRNA precursor²³, while it also acts as intercalator similarly to daunorubicin and idarubicin. 354 The RNA synthesis inhibitor plicamycin showed the largest difference in activity between *TP53* 355 mutated and WT *TP53* samples. Plicamycin selectively targets genes with GC-rich promoter 356 sequences, activates any remaining wild-type p53 and inhibits the transcriptional regulator SP1 from DNA binding, including to the promoter of *TP53*²³. The enrichment of pathways 358 associated with mRNA processing and chromatin modulation suggests altered transcriptional 359 regulation and DNA replication in *TP53* mutated MM, which is similar to findings in other 360 cancers^{9,18,24,25}.

361 When exploring potential confounding genomic factors that may contribute to the enhanced 362 drug sensitivity profile in *TP53* mutated MM cells, we noticed that *TP53* mutations were 363 frequently accompanied by *KRAS* mutations, which was not observed in monoallelic *TP53* 364 MM. However, when we compared the drug response profiles of samples with *TP53* mutation 365 and WT *KRAS* to samples with both *TP53* and *KRAS* mutation, we only found 5 drugs were 366 significantly affected by the presence of a *KRAS* mutation, with the *KRAS* mutation conferring 367 a slight negative effect on the activity of these drugs. These results indicate that mutation to 368 *TP53* is the main contributor to the enhanced drug sensitivity and altered transcriptomic and 369 proteomic profiles of *TP53* mutated cells. Further research is needed to understand the 370 mechanisms leading to enhanced sensitivity to drugs such as plicamycin and doxorubicin and

371 their impact on MM cells and disease models with mutated *TP53*. Additionally, other drugs 372 that were not included in our panel could be effective for patients with *TP53* mutation positive 373 MM. For example, our proteomic analysis showed elevated levels of XPO1, the target of 374 approved MM drug selinexor, and its cofactor RANBP3, which are exclusively responsible for 375 transporting p53 out of the nucleus^{26,27}. Considering the enhanced activity of several 376 chemotherapies in *TP53* mutated CD138+ MM cells, newer agents such as the antibody-drug 377 conjugate blenrep and peptide-drug conjugate melflufen might also provide increased efficacy 378 for patients with *TP53* mutated MM. In addition, novel therapeutic approaches, such as CAR-379 T cell therapies, bispecific and monoclonal antibodies have shown promising results for MM 380 in clinical settings²⁸. Our drug screening, however, was limited to small molecules, which were 381 tested, depending on cell availability, on isolated CD138+ MM cells without the supporting 382 immune microenvironment. Nevertheless, the results revealed targetable vulnerabilities in 383 TP53 mutated MM, which could be investigated further for future therapeutic development.

384 While our comprehensive profiling showed that mutation to *TP53* can impact *ex vivo* drug 385 response as well as the transcriptomic and proteomic profiles to cells with the mutation, we 386 have only recently gained understanding of the significance of this aberration on patient 387 outcome. The adverse effect of *TP53* mutation on overall survival suggests that early detection 388 of subclonal *TP53* mutations could potentially predict faster disease progression after relapse 389 and allow for earlier intervention. This would be particularly important for patients without 390 del(17p) but with mutated *TP53*, as these patients may not be correctly stratified and are less 391 likely to receive optimized care.

392 In conclusion, our study offers translational insights into the implications of *TP53* mutations in 393 MM. Our findings elucidate key molecular aspects from genomic to proteomic landscapes, 394 guiding future research and therapeutic strategies for this subgroup of patients. As the 395 complexities of MM continue to be unraveled with the application of advanced technologies, 396 we will gain better understanding of the impact of genetic mutations like *TP53*, and how these 397 can shape the future of MM risk-stratification and treatment. These findings emphasize the 398 importance of personalized medicine approaches in oncology and provide rationale for the 399 development of multiple therapeutic strategies and treatment of *TP53* mutated MM.

400

401 **FIGURE LEGENDS**

402 **Table 1.** Summarized characteristics of MM patients providing samples to the FIMM cohort

403 and the analyses performed.

404 **Table 2**. *TP53* mutations detected in patients from the FIMM dataset.

405 • Figure 1. Workflow and patient stratification according to *TP53* **status. (A) CD138+ cells from** 406 167 bone marrow samples were molecularly and functionally profiled depending on viable 407 cell numbers. (B) Dataset used from the MMRF-CoMMpass study for validation purposes. (C) 408 Comparison of patient *TP53* status with and without DNA sequencing in the MMRF-409 CoMMpass patient population. Remaining patient proportion in grey represents wild-type 410 (WT) *TP53* status.

411 • Figure 2. Ex vivo drug screening identifies compounds with enhanced activity in MM patient 412 **samples with** *TP53* **mutation.** (A) Volcano plot illustrating the comparison of drug sensitivity 413 between MM samples with monoallelic *TP53* and WT *TP53* samples. No compounds 414 presented significantly increased sensitivity for samples with monoallelic *TP53*. (B) Samples 415 harboring *TP53* mutations, irrespective of del(17p) status, exhibit increased sensitivity to a 416 range of therapeutic agents. The volcano plot's x-axis shows the median difference in DSS 417 between the two groups, while the y-axis represents the negative logarithm (base10) of the 418 p-value obtained from the Wilcoxon rank-sum test. Data points represent individual 419 compounds, with the datapoint size reflecting the number of samples tested per compound. 420 Significant hits with median difference above 5 are highlighted in red, and a few additional 421 selected compounds are also labeled but remain in grey. (C) Box plot showing the distribution 422 of *ex vivo* sensitivity to selected compounds. DSS below 10 indicates overall resistance to the 423 compounds. The center line represents the median value. The upper and lower limits of the 424 box represent the upper (75th percentile) and lower (25th percentile) quartiles, respectively. 425 The whiskers extend to the largest and smallest values within 1.5 times the interquartile range 426 from the quartiles. Points beyond the whiskers are outliers and are plotted individually. 427 Statistical significance indicated as $*$ p-value < 0.05, $**$ p-value < 0.01, $***$ p-value < 0.001 by 428 Wilcoxon rank-sum test.

429 • Figure 3. Co-occurrence of other mutations in addition to *TP53* **aberrations. (A) Heatmap of** 430 common mutations in samples with *TP53* aberrations from the FIMM cohort. *KRAS* mutations 431 in samples with *TP53* mutation are overrepresented compared to del(17p) alone. (B) Heatmap 432 of common mutations in patients containing *TP53* aberrations from the MMRF-CoMMpass 433 study dataset. (C) Frequency of mutations in the *TP53* coding region from 52 patients of the

434 MMRF-CoMMpass study according to available data. The illustration of the functional 435 domains in the p53 protein includes the transcriptional activation domains (TAD, in blue and 436 green), the DNA binding domain (DBD, in red) and the tetramerization domain (TD, in orange). **437 • Figure 4. Genes sets associated with cellular proliferation are enriched in TP53 mutated MM.** 438 (A) Differential gene expression (DGE) in *TP53* mutated MM samples compared to WT *TP53* 439 samples from the FIMM dataset. The x-axis shows the log2 fold change in expression and the 440 y-axis shows the negative log10 of the p-value. Red dots represent genes with increased 441 expression in *TP53* mutated MM, while decreased expression is represented with blue dots. 442 (B) DGE analysis from the CoMMpass dataset, represented similarly, however the y-axis shows 443 the negative log10 of the adjusted p-value. (C) Gene set enrichment analysis (GSEA) results 444 compared between both datasets, ordered by normalized enrichment score (NES) of the 445 FIMM dataset. The gene sets shown have an adjusted p-value ≤ 0.1 in at least one of the two 446 datasets. (D) GSEA network plot illustrating the relationship between differentially expressed 447 genes from selected hallmark gene sets. The genes shown are differentially expressed in 448 CoMMpass dataset.

449 **Figure 5. Proteins involved in RNA processing are more prevalent in** *TP53* **mutated MM cells.** 450 (A) Significantly increased expression of proteins from samples with *TP53* mutation compared 451 to WT *TP53* samples is represented in a volcano plot. The x-axis shows the difference in the 452 mean level of protein expression, with the y-axis representing negative log10 of the p-value. 453 Red dots represent genes with increased expression in *TP53* mutated MM, while decreased 454 expression is represented with blue dots. (B) GSEA of significant proteins on the hallmarks 455 database reaffirm the results from the gene expression analysis, which showed gene sets 456 associated with increased proliferation are enriched in *TP53* mutated MM. (C) The ten most 457 positively and five most negatively enriched gene sets on GO C5 database. Gene sets are 458 presented in descending order of normalized enrichment score (NES). (D) Analysis shows 459 significant reduction in survival for patients with *TP53* mutation compared to WT *TP53* (OS: 460 2.004 [95% CI: 1.314-3.057] p = 0.001). Monoallelic loss of *TP53* (cut-off ≥ 20%) suggests a 461 comparatively better prognosis (OS: HR = 1.264 [95% CI: 0.681-2.343] p = 0.458). (E) 462 Monoallelic loss of *TP53*, with presence of WT *TP53* shows short progression free survival 463 (PFS) of 530 days (PFS: HR = 1.356 [95% CI: 0.997-1.846] p = 0.053). On the other hand, 464 presence of *TP53* mutation shows a delayed median progression 628 days (PFS: HR = 1.024) 465 $[95\%$ CI: 0.832-1.260] p = 0.823), WT patients' median PFS was 689 days.

466

467 **ACKNOWLEDGMENTS**

468 The authors thank the patients for their consent and generosity to use their samples and data. 469 We are grateful for the support of the FIMM Technology Center Genomics and High 470 Throughput Biomedicine Units. In addition, we thank the Multiple Myeloma Research 471 Foundation (MMRF) for making their datasets publicly available. The Finnish Hematology 472 Registry and Biobank and the Helsinki Hematology Research Unit are acknowledged for 473 contributions to the sample collection and clinical data.

474

475 **AUTHOR CONTRIBUTIONS**

476 C.A.H., D.T., and M.M.M. contributed to the study conceptualization. D.T., J.M., A.P., M.S., and 477 M.M.M. performed experimental work. S.E. performed data normalizations for proteomic and 478 sequencing data. K.D., P.D., D.B. and P.O'G. performed LC-MS/MS experiments and 479 contributed to proteomics data analysis. D.T. performed data analysis and interpretation with 480 N.I.'s contribution. J.L., R.S. and P.A. provided patient samples and contributed clinical data. 481 D.T., J.J.M., I.V., N.I. and C.A.H. contributed to data management. D.T. and C.A.H. wrote the 482 article. C.A.H. supervised the study and provided infrastructure support. All authors critically 483 read and approved the final version of the article.

484

485 **CONFLICTS OF INTEREST**

 C.A.H has received funding from BMS/Celgene, Kronos Bio, Novartis, Oncopeptides, WNTResearch, and Zentalis Pharmaceuticals for research unrelated to this work, and honorarium from Amgen and Autolus. R.S. has received research funding from Amgen, BMS/Celgene and Takeda administered by Hospital Science Centers, unrelated to this work. All other authors declare no conflicts of interest.

491

492 **REFERENCES**

493 1. Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a

494 glance into future. *Haematologica*. 2020;105(10):2358–2367.

495 2. Wiedmeier-Nutor JE, Bergsagel PL. Review of Multiple Myeloma Genetics including 496 Effects on Prognosis, Response to Treatment, and Diagnostic Workup. Life (Basel). 497 2022;12(6):812. 498 3. Corre J, Perrot A, Caillot D, et al. del(17p) without TP53 mutation confers a poor 499 prognosis in intensively treated newly diagnosed patients with multiple myeloma. *Blood*. 500 2021;137(9):1192–1195. 501 4. Chavan SS, He J, Tytarenko R, et al. Bi-allelic inactivation is more prevalent at relapse in 502 multiple myeloma, identifying RB1 as an independent prognostic marker. *Blood Cancer J.* 503 2017;7(2):e535. 504 5. Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, Double-Hit, group of newly 505 diagnosed myeloma iden.fied by genomic analysis. *Leukemia*. 2019;33(1):159–170. 506 6. Flynt E, Bisht K, Sridharan V, et al. Prognosis, Biology, and Targeting of TP53 507 Dysregulation in Multiple Myeloma. Cells. 2020;9(2):287. 508 7. Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving 509 tumor suppressor genes underlie relapse in myeloma. *Blood*. 2016;128(13):1735–1744. 510 8. Corre J, Munshi NC, Avet-Loiseau H. Risk factors in multiple myeloma: is it time for a 511 revision? *Blood*. 2021;137(1):16–19. 512 9. Chen X, Zhang T, Su W, et al. Mutant p53 in cancer: from molecular mechanism to 513 therapeutic modulation. *Cell Death Dis.* 2022;13(11):1-14. 514 10. Majumder MM, Silvennoinen R, Anttila P, et al. Identification of precision treatment 515 strategies for relapsed/ refractory multiple myeloma by functional drug sensitivity 516 testing. Oncotarget. 2017;8(34):56338-56350. 517 11. Malani D, Kumar A, Brück O, et al. Implementing a Functional Precision Medicine Tumor 518 Board for Acute Myeloid Leukemia. *Cancer Discov*. 2022;12(2):388–401. 519 12. Kuusanmäki H, Kytölä S, Vänttinen I, et al. *Ex vivo* venetoclax sensitivity testing predicts 520 treatment response in acute myeloid leukemia. *Haematologica*. 2023;108(7):1768–1781. 521 13. Kropivsek K, Kachel P, Goetze S, et al. Ex vivo drug response heterogeneity reveals 522 personalized therapeutic strategies for patients with multiple myeloma. *Nat Cancer*. 523 2023;4(5):734–753. 524 14. Gencel-Augusto J. Lozano G. p53 tetramerization: at the center of the dominant-negative 525 effect of mutant p53. *Genes Dev.* 2020;34(17–18):1128–1146.

- 526 15. Yadav B, Pemovska T, Szwaida A, et al. Quantitative scoring of differential drug sensitivity
- 527 for individually optimized anticancer therapies. *Sci Rep.* 2014;4(1):5193.
- 528 16. Richardson PG, Mitsiades CS, Laubach JP, et al. Inhibition of heat shock protein 90
- 529 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
- 530 *British Journal of Haematology.* 2011;152(4):367-379.
- 531 17. Martello M, Poletti A, Borsi E, et al. Clonal and subclonal TP53 molecular impairment is
- 532 associated with prognosis and progression in multiple myeloma. *Blood Cancer J.*
- 533 2022;12(1):15.
- 534 18. Hu J, Cao J, Topatana W, et al. Targeting mutant p53 for cancer therapy: direct and 535 indirect strategies. *Journal of Hematology & Oncology*. 2021;14(1):157.
- 536 19. Lindström MS, Bartek J, Maya-Mendoza A. p53 at the crossroad of DNA replication and 537 ribosome biogenesis stress pathways. *Cell Death Differ*. 2022;29(5):972–982.
- 538 20. Werner H, LeRoith D. Hallmarks of cancer: The insulin-like growth factors perspective. 539 *Front. Oncol.* 2022;12:1055589.
- 540 21. Cui D, Qu R, Liu D, et al. The Cross Talk Between p53 and mTOR Pathways in Response to 541 Physiological and Genotoxic Stresses. *Front. Cell Dev. Biol.* 2021;9:775507.
- 542 22. Kang J, Brajanovski N, Chan KT, et al. Ribosomal proteins and human diseases: molecular 543 mechanisms and targeted therapy. *Sig Transduct Target Ther*. 2021;6(1):1–22.
- 544 23. Burger K, Mühl B, Harasim T, et al. Chemotherapeutic drugs inhibit ribosome biogenesis 545 at various levels. *J Biol Chem*. 2010;285(16):12416–12425.
- 546 24. Bhakat KK, Ray S. The FAcilitates Chromatin Transcription (FACT) complex: Its roles in
- 547 **DNA repair and implications for cancer therapy.** *DNA Repair***. 2022;109:103246.**
- 548 25. Zhu J, Sammons MA, Donahue G, et al. Gain-of-function p53 mutants co-opt chromatin 549 pathways to drive cancer growth. *Nature*. 2015;525(7568):206–211.
- 550 26. Golomb L, Bublik DR, Wilder S, et al. Importin 7 and exportin 1 link c-Myc and p53 to
- 551 regulation of ribosomal biogenesis. *Mol Cell*. 2012;45(2):222–232.
- 552 27. Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1 from biology 553 to targeted therapy. *Nat Rev Clin Oncol*. 2021;18(3):152–169.
- 554 28. Rasche L, Hudecek M, Einsele H. CAR T-cell therapy in multiple myeloma: mission 555 accomplished? *Blood*. 2024;143(4):305–310.

- 556 29. Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European Myeloma Network
- 557 on interphase FISH in multiple myeloma and related disorders. *Haematologica*.
- 558 2012;97(8):1272–1277.
- 559 30. Karjalainen R, Pemovska T, Popa M, et al. JAK1/2 and BCL2 inhibitors synergize to
- 560 counteract bone marrow stromal cell–induced protection of AML. *Blood*.
- 561 2017;130(6):789–802.
- 562 31. Kontro M, Kuusanmäki H, Eldfors S, et al. Novel activating STAT5B mutations as putative 563 drivers of T-cell acute lymphoblastic leukemia. *Leukemia*. 2014;28(8):1738–1742.
- 564 32. Eldfors S, Kuusanmäki H, Kontro M, et al. Idelalisib sensitivity and mechanisms of disease 565 progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. *Leukemia*.
- 566 2017;31(1):51–57.
- 567 33. Kumar A, Kankainen M, Parsons A, et al. The impact of RNA sequence library
- 568 construction protocols on transcriptomic profiling of leukemia. *BMC Genomics*. 569 2017;18(1):629.
- 570 34. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for 571 RNA-seq data with DESeq2. *Genome Biology*. 2014;15(12):550.
- 572 35. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting 573 omics data. *Innovation*. 2021;2(3):.
- 574 36. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A
- 575 knowledge-based approach for interpreting genome-wide expression profiles.
- 576 *Proceedings of the National Academy of Sciences*. 2005;102(43):15545-15550.
- 577 37. Liberzon A, Subramanian A, Pinchback R, et al. Molecular signatures database (MSigDB) 578 3.0. *Bioinformatics*. 2011;27(12):1739-1740.
- 579 38. Goldsmith SR, Fiala MA, Dukeman J, et al. Next Generation Sequencing-based Validation
- 580 of the Revised International Staging System for Multiple Myeloma: An Analysis of the
- 581 MMRF CoMMpass Study. *Clinical Lymphoma Myeloma and Leukemia*. 2019;19(5):285–
- 582 289.
- 583 39. Therneau T. A package for survival analysis in R. 2020;
- 584 40. Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: Drawing Survival Curves using 585 "ggplot2." 2021;


```
Figure 2
```


Figure 3

B CoMMpass dataset

 θ

Figure 4

SPC₂₄

20 40 60

Figure 5

Table 1. Summarized characteristics of MM patients providing samples to the FIMM cohort and the analyses performed.

Table 2. *TP53* mutations detected in patients from the FIMM dataset

Sample ID	Disease stage	del(17p)	Mutation Frequency in Tumor	Somatic P-Value	Chromosome Location	Base Change	Amino Acid Change Variant Effect		Protein Domain
MM005 2	Relapse	Yes	0.2222	0.041812	Chr17:7572961	A > G	L383P	non synonymous coding	Regulatory Domain
MM007 1	Relapse	No	0.3359	1.2718e-14	Chr17:7577534	C > A	R249S	non synonymous coding	DNA-Binding Domain
MM010 1	Relapse	Yes	0.86	8.4891e-24	Chr17:7578185	GC > G	-221	frame shift	
MM025_1	Relapse	Yes	0.4175	3.5168e-17	Chr17:7577574	T>C	Y236C	non synonymous coding	DNA-Binding Domain
MM033 4	Relapse	Yes	0.2087	2.591e-05	Chr17:7578371	C > G	G187R	non synonymous coding	DNA-Binding Domain
MM041_1	Relapse	Yes	0.5833	6.9734e-07	Chr17:7577518	TGATGGTGAG>T	LTI252-	codon deletion	
MM042_1	Relapse	Yes	0.7536	1.2896e-12	Chr17:7577535	C > A	R249M	non synonymous coding	DNA-Binding Domain
MM043 2	Relapse	Yes	0.7857	4.8947e-29	Chr17:7578242	C > G	V203L	non synonymous coding	DNA-Binding Domain
MM043 2	Relapse	Yes	0.125	0.0034623	Chr17:7578204	A > C	S215R	non synonymous coding	DNA-Binding Domain
MM055 1	Relapse	No	0.6436	1.7451e-24	Chr17:7578440	T>C	K164E	non synonymous coding	DNA-Binding Domain
MM060 2	Relapse	No	0.1314	0.00056092	Chr17:7577538	$C>$ T	R2480	non synonymous coding	DNA-Binding Domain
MM064 1	Diagnosis	No	0.4667	1.0176e-05	Chr17:7578190	T>C	Y220C	non synonymous coding	DNA-Binding Domain
MM064 1	Diagnosis	No	0.434	0.00016009	Chr17:7578176	C > A		splice site donor	
MM065 1	Diagnosis	Yes	0.1296	0.0016255	Chr17:7577022	G > A	R306*	stop gained	DNA-Binding Domain
MM085 2	Relapse	No	0.3265	1.0205e-06	Chr17:7574034	C > G	$c.994-1G > C$	splice acceptor variant+intron variant	
MM098 1	Relapse	Yes	0.623	1.9092e-17	Chr17:7578291	T>C		splice site acceptor	DNA-Binding Domain
MM107_1	Relapse	Yes	0.6579	9.7397e-14	Chr17:7579529	C>7	p.Trp53*/c.158G>A	stop gained	DNA-Binding Domain
MM122 1	Diagnosis	No	0.0929	0.011409	Chr17:7578433	G > T	S166*	stop gained	DNA-Binding Domain
MM135 1	Relapse	Yes	0.9478	3.7734e-39	Chr17:7578479	G > T	P151T	non synonymous coding	DNA-Binding Domain
MM137_1	Relapse	No	0.3817	9.5371e-10	Chr17:7577506	C > G	D259H	non synonymous coding	DNA-Binding Domain